Boonlogic offers AVIS™, an AI‑driven visual inspection platform for pharmaceutical manufacturers that trains on as few as 500 units of compliant product, eliminating the need for defect libraries. The system provides real‑time detection of unknown defects at speeds over 50 parts per minute, delivering accuracy comparable to or better than human inspectors while maintaining GMP‑compliant audit trails and electronic signatures.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pharmaceutical manufacturers rely on manual visual inspection or traditional vision systems that require extensive defect libraries and slow, low-throughput processes, leading to inspection bottlenecks, inconsistent quality, and difficulty meeting GMP documentation requirements.
Solution
AVIS™ is an AI-driven visual inspection platform that trains exclusively on images of compliant product, eliminating the need for pre‑labeled defect sets. By using as few as 500 units of good product, the system builds a model that detects unknown defects in real time at production speeds of over 50 parts per minute. The solution delivers inspection accuracy comparable to or better than trained human inspectors while providing consistent, repeatable results and full audit trails that satisfy FDA 21 CFR Part 11 and EU Annex 11 compliance. This enables pharma lines to maintain continuous flow, reduce reliance on manual labor, and improve overall quality control.
Target Audience
Primary customers are pharmaceutical manufacturers and contract manufacturing organizations that need automated, high‑speed visual inspection for tablet, capsule, and other solid‑dose products to meet regulatory quality standards.
Features
- Rapid model training using only 500 compliant units, no defect image libraries required
- High‑throughput inspection capability of 50+ parts per minute, preventing production slowdowns
- Real‑time detection of unknown defects with AI accuracy equal to or exceeding human inspectors
- Consistent, repeatable inspection results with built‑in statistical process control
- Full GMP‑compliant data capture and electronic signatures supporting 21 CFR Part 11 and EU Annex 11
- Scalable deployment across diverse pharmaceutical product formats, including difficult‑to‑inspect items